A leading centre for paediatric health and hub for excellence in paediatric oncology, the Centre de cancérologie Charles-Bruneau at the CHU Sainte-Justine, a Santé Québec establishment, ensures the diagnosis and treatment of close to 65% of paediatric cancers in Quebec. Its leading-edge expertise in both research and clinical care make it a North American leader recognized for its attention to the needs of young patients and their families.
The Centre houses a centre of excellence in bone marrow and umbilical cord blood transplants, as well as other cellular therapies, including CAR T-cell therapy. This groundbreaking immunotherapy involves reprogramming a patient’s own cells to fight cancers that are resistant to conventional treatments.
The establishment acts as the centre responsible for the paediatric cancer network, collaborating with the three other university hospital centres to ensure the coordination and quality of care in oncology for all of Quebec.
This new five-year commitment of $21,281,776 to CHU Sainte-Justine will help advance precision medicine, better target relapsed and refractory cancers, prevent long-term effects, and support specialized research infrastructure in paediatric oncology.
Through this major commitment, the Fondation Charles-Bruneau reaffirms its deep conviction that transforming care requires collaboration and research grounded in the real needs of children.
“Thanks to scientific advances, precision medicine is becoming a reality in paediatric hematology-oncology at the CHU Sainte-Justine and all over Quebec. This progress allows us to envision the fulfilment of Charles Bruneau’s dream, now our collective dream: a cancer-free childhood and a cure without after-effects.”
